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Abstract The purpose of this study was to compare the psychometric properties of the Screen 
for Cognitive Impairment in Psychiatry (SCIP) when applied to patients diagnosed with 
schizophrenia (n = 126) or bipolar I disorder (n = 76), and also to compare the cognitive 
impairment in both samples of patients and a control group (n = 83) using the SCIP and a 
complete neuropsychological battery. The SCIP is a scale intended to quickly and easily assess 
cognitive impairment in patients with severe psychiatric disorders. The results showed firstly 
that, in terms of internal consistency, temporal stability, dimensional structure, and criterion-
referenced validity, the SCIP provides reliable and valid scores at an equivalent level in both 
schizophrenia and bipolar I disorder samples. Secondly, it showed that differential cognitive 
impairment between the two patient groups occurs only in verbal memory, although the effect 
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Resumen El objetivo del estudio fue comparar las propiedades psicométricas del test Screen 
for Cognitive Impairment in Psychiatry (SCIP) en pacientes diagnosticados de esquizofrenia (n = 
126) o trastorno bipolar I (n = 76). Además, el deterioro cognitivo se comparó con un grupo con-
trol (n = 83) empleando el SCIP y una batería neuropsicológica completa. El test SCIP es una 
escala que evalúa rápida y fácilmente el deterioro cognitivo en trastornos psiquiátricos graves. 
En términos de consistencia interna, estabilidad temporal, estructura dimensional y validez 
de criterio, el SCIP proporciona resultados al mismo nivel de fiabilidad y validez en pacientes 
con esquizofrenia o trastorno bipolar I. Además, demostró que el deterioro cognitivo diferencial 
entre los dos grupos de pacientes se produce solo en la memoria verbal, aunque el tamaño 
del efecto de esta diferencia es pequeño. Por último, y frente al grupo control, se confirma el 
deterioro cognitivo a todos los niveles en ambos grupos de pacientes utilizando tanto el SCIP 
como la batería neuropsicológica, lo que indica que el SCIP es una buena herramienta de detec-
ción para los déficits cognitivos en esquizofrenia y trastorno bipolar, y útil en la práctica clínica 
habitual para profesionales de la salud.
© 2013 Asociación Española de Psicología Conductual. Publicado por Elsevier España, S.L.  
Todos los derechos reservados.
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Several studies have shown that cognitive functions are 
impaired both in patients with schizophrenia and those 
with bipolar I disorder, and these impairments have a real 
impact on the daily functioning of patients with these 
disorders (Bowie et al., 2010; Tabarés-Seisdedos et al., 
2008). The early detection of neurocognitive impairment is 
a challenge, particularly with respect to orientation of 
treatment (Balanzá-Martínez et al., 2010).
The Screen for Cognitive Impairment in Psychiatry (SCIP) 
(Pino et al., 2006; Purdon, 2005) was designed for detecting 
cognitive deficits in several psychotic and affective 
disorders. It may be administered without the need for 
additional equipment (only pencil and paper) and requires 
less than 15 minutes, which allows it to be easily 
administered in daily medical practice in different settings 
without an extra burden of administration. There are three 
alternative forms of the scale available to minimize learning 
effects in prospective evaluations. The SCIP consists of five 
brief peformance subtests including a Working Memory Test 
(WMT), a Verbal Learning Test-Immediate Recall (VLT-I), a 
Verbal Fluency Test (VFT), a Verbal Learning Test-Delayed 
Recall (VLT-D), and a Processing Speed Test (PST). The 
original SCIP version is in English. The origin and nature of 
the scale have previously been explained in detail both for 
the original instrument (Purdon, 2005) and for the process 
of translation and adaptation of the Spanish version (Pino 
et al., 2006). Recently, its psychometric properties have 
been validated in a sample of psychiatric patients with 
schizophrenia (Pino et al., 2008) or bipolar I disorder 
(Guilera et al., 2009). In addition, useful cut-off points 
have been established to facilitate the use of the SCIP in 
both clinical and research settings (Rojo et al., 2010), and 
a recent report has provided evidence that the SCIP may 
have better predictive value than other screening tools for 
detecting a global cognitive deficit (Cuesta et al., 2011).
The previous investigations of the psychometric 
properties of the Spanish version of the SCIP (SCIP-S) have 
provided empirical support for the validity and reliability of 
the test in schizophrenia (Pino et al., 2006) and bipolar I 
disorder (Guilera et al., 2009) patients, despite small 
differences in the values obtained with regard to internal 
consistency, temporal stability, dimensional structure and 
relationships with other variables. The study described 
below will discuss further the statistical equivalency of the 
psychometric properties of the SCIP-S with more direct 
comparisons between the values obtained from patients 
with schizophrenia or bipolar I disorder. The main aim is to 
determine whether the SCIP is equally reliable and valid for 
both psychiatric samples. The secondary aims would be to 
assess the value of the SCIP for detection of cognitive 
impairment in each psychiatric samples relative to a 
healthy control group, and to directly compare the 
psychiatric samples to assess any differences in the severity 
or the profile of cognitive deficits detected by the SCIP in 
each group in relation to the deficits detected by a more 
detailed neuropsychological examination.
Method
Participants
A total of 202 psychiatric patients participated in this study. 
The sample included 126 patients diagnosed with 
schizophrenia (73% men; mean age 36.66; SD = 8.38) and 76 
with bipolar I disorder (45% men; mean age 40.30; SD = 
8.98). The clinical sample was recruited through 40 
outpatient psychiatric clinics across Spain. All patients 
were evaluated by experienced psychiatrists and met DSM 
IV-TR criteria (American Psychiatric Association, 2000) for 
size of the difference is small. Finally, compared with the control group, cognitive impairment 
was present at all levels in both groups of patients using both the SCIP and the neuropsychological 
battery, which indicates that the SCIP is a good screening tool for cognitive deficits in 
schizophrenia and bipolar and useful in clinical practice for healthcare professionals.
© 2013 Asociación Española de Psicología Conductual. Published by Elsevier España, S.L.  
All rights reserved.
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the corresponding diagnosis. The inclusion criteria for 
patients were 18-55 years of age, and no changes in drug 
regimen or dose during the study. For patients with 
schizophrenia was required a stable phase of the illness 
defined by no hospitalization in the past 3 months, a total 
score under 70 on the Positive and Negative Syndrome Scale 
(PANSS, Kay, Flszbein, & Opfer, 1986; Peralta & Cuesta, 
2004), and a score under 3 on all seven positive symptom 
items of the PANSS. For patients with bipolar I disorder was 
required a stable phase of the illness defined by at least 
6 months in remission, a Hamilton Depression Scale (HAMD) 
(Hamilton, 1960) score less than 8, a Young Mania Rating 
Scale (YMRS) (Young, Biggs, Ziegler, & Meyer, 1978) score 
less than 6. In both cases, patients were not included if 
they were suffering from a severe medical or neurological 
condition, or another psychiatric disorder that required 
treatment, if they were participating in a clinical trial, or 
exhibiting difficulties with reading or writing. Relative to 
the schizophrenia sample, the bipolar I disorder sample was 
older (t(200) = 2,91, p < .05), and had a larger proportion of 
women (chi square = 16,15, p < .05). The schizophrenia 
sample tended to be single (87%), living with their birth 
families (73%), unemployed on disability benefits (41%), 
and educated to at least a secondary level (60%). The 
bipolar I disorder group tended also to be single (46%) and 
living with their family (46%), with many working (38%) 
and having achieved at least a secondary education (61%). 
Further description of the demographic characteristics of 
the groups is available in our prior reports (Guilera et al., 
2009; Pino et al., 2008). 
A control group composed of 83 healthy individuals (59% 
men; mean age 38.07; SD=8.48) also participated in the 
study. The control sample was statistically matched with 
both clinical samples combined on sex, age, and educational 
level, and they were free of significant symptoms of 
psychiatric il lness assessed with the interview 
Comprehensive Assessment of Symptoms and History (CASH) 
(Andreasen, Flaum, & Arndt, 1992). Controls were excluded 
if they had severe medical or neurological problems, met 
criteria for a psychiatric disorder, were participating in a 
clinical trial, were illiterate, or having any first degree 
relative with mental illness. There were no significant 
differences in terms of age, sex or educational level 
compared with the patient samples (all p values > .05). This 
group was statistically matched with both samples 
combined, so there were no significant differences in terms 
of age or sex compared with the patient samples (all 
p values > .05). The control group tended to be married 
(61%), with many working (86%) and having achieved at 
least a secondary education (68%). All participants were 
asked for their written consent to participate in the study, 
and the protocol and procedures were reviewed and 
approved by the University of Barcelona Research 
Committee.
Instruments
The SCIP was designed to detect cognitive deficits in several 
psychotic and affective disorders. It can be administered 
without the need for additional equipment (only pencil and 
paper) and requires around 15 minutes to complete. Three 
alternative forms of the scale are available to facilitate 
repeated testing while minimizing learning effects. The 
SCIP includes a Verbal Learning Test-Immediate (VLT-I), a 
Working Memory Test (WMT), a Verbal Fluency Test (VFT), 
a Verbal Learning Test-Delayed (VLT-D), and a Processing 
Speed Test (PST). The original version of the SCIP is in 
English (Purdon, 2005), while the rationale, and 
development of the Spanish version (SCIP-S) was described 
in a previous publication (Pino et al., 2006). The SCIP-S has 
shown adequate psychometric properties for detection of 
cognitive impairment in patients with schizophrenia (Pino 
et al., 2008) and type I bipolar disorder (Guilera et al., 
2009). Psychometric properties tested included feasibility, 
reliability, construct and criteria validities. Feasibility was 
supported by a brief administration time (approximately 
15 minutes) in patients with either schizophrenia or bipolar 
type I, and minimal scoring errors. The reliability of the 
SCIP was confirmed by good equivalence of forms, 
acceptable stability (ICC range .74 to .90 in schizophrenia 
subjects and .59 to .87 in bipolar type I patients) and 
adequate internal consistency (Cronbach’s alpha of .73 
and .74, respectively). Construct validity was granted by 
extraction of a single factor (accounting 50% and 52% of the 
variance, respectively in patients with schizophrenia or 
bipolar type I disorder). The SCIP scale was correlated, in 
both type of patients, with corresponding neuropsychological 
instruments, with Pearson’s r between .38 and .60 and the 
scale effectively discriminated between patients with any 
of such psychiatric conditions and controls.
Procedure
The SCIP was administered to the control group on one 
occasion only, and to patients on three occasions separated 
by an interval of one week (± 2 days). The order of 
administration of the three parallel forms of the SCIP was 
balanced in the first two visits, followed by a re-test with 
last version administered (e.g. 1-2-2, 1-3-3, 2-1-1, 2-3-3, 
3-1-1, 3-2-2). Furthermore, to assess the merits of the SCIP 
relative to a more extensive battery of neuropsychological 
instruments, at the baseline visit all subjects were 
administered twelve additional standardized cognitive 
instruments including tests of immediate and delayed word 
recall (WMS-III Word List I and II), processing speed (WAIS-III 
Digit Symbol Coding, Trail Making A and B, WAIS-III Digit 
Symbol Coding, WAIS-III Symbol Search), working memory 
(WAIS-III Arithmetic, Digit Span, and Letter-Number 
Sequencing), language (Semantic Fluency, and WAIS-III 
Vocabulary), and problem solving (Wisconsin Card Sorting 
Test, WCST). The selection of this battery was in accordance 
with the criteria included in Carretero-Dios and Pérez 
(2007), and Jurado and Pueyo (2012). Additional details of 
the instruments, recruitment procedures, and the design for 
data collection design are available in our prior reports 
(Guilera et al., 2009; Pino et al., 2008). 
Data analysis
The two studies mentioned above showed that there were 
no differences between the parallel forms of the SCIP in 
either of the patient groups, so the analysis of this study 
was performed with the three forms combined. The analysis 
of the psychometric properties of the scale followed the 
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recommendations from Carretero-Dios and Pérez (2007). In 
assessing the internal consistency of the SCIP, Cronbach’s 
alpha coefficient was computed with the scores from the 
first visit, and in assessing temporal stability, intraclass 
correlation coefficients (ICC) were calculated for each sub-
test of the SCIP with the scores from the second and third 
visit. Feldt’s W statistic was used to compare the internal 
consistency coefficients obtained in both samples (Feldt, 
1969) and the corresponding intraclass correlation 
coefficients (Kraemer, 1981). The null hypothesis of this 
statistic suggests that the coefficients of sample 1 and 
sample 2 are equal and the statistic is defined as 
W = (1−α1)/ =1−α2) in the case of temporal stability, the 
coefficients of internal consistency should be replaced by 
the corresponding ICCs – which follows an F distribution 
with N1−1 and N2−1 degrees of freedom. The dimensional 
structure of the SCIP was assessed with a principal 
component analysis and the comparison between the two 
structures by computing Tucker’s congruency index (Tucker, 
1951) and the identity coefficient (Zegers & ten Berge, 
1985). Finally, the convergence of the SCIP sub-test scores 
with the neuropsychological battery scores was assessed 
using Pearson correlation coefficients, which in turn were 
compared between patients with schizophrenia and bipolar 
disorder using Fisher’s Z. 
The capability of the SCIP to discriminate among the 
schizophrenia, bipolar, and matched healthy control 
samples was assessed by multivariate (with Bonferroni 
adjustment) and univariate comparisons of the baseline 
SCIP subscale scores and total score, respectively. Because 
of the differences found in the demographic variables 
between the patient samples, the analysis also included 
sex as a factor and age as a covariate. The magnitude of 
those differences in each subscale score and the total score 
was calculated with Cohen’s d, representing the difference 
between the scores of the two compared groups divided by 
the pooled standard deviation. Additionally, this 
multivariate approach was used for between group 
comparisons of performance on the neuropsychological 
battery by entry of test scores corresponding to total items 
correct on Word List I, Word List II, Digit Symbol Coding, 
Symbol Search, Arithmetic, Letter-Number Sequencing, 
Semantic Fluency, and Vocabulary, as well as time to 
complete TMT-A and TMT-B, and total errors and total 
perseverative errors on the WCST.
Results
Equivalency between psychometric properties
Internal consistency and temporal stability. Cronbach’s 
alpha coefficient was very similar for both diagnoses; in the 
sample of patients with schizophrenia it was .73, while for 
patients with bipolar I disorder it reached a value of .74. 
Feldt’s W statistic of comparison between the two 
coefficients reached a value of 1.03 (p = .56), leading to 
acceptance of the null hypothesis of equality between the 
internal consistency indexes. Regarding test-retest 
reliability, Table 1 shows the ICC values in both groups for 
all subtests and the SCIP total score, as well as their Feldt’s 
W statistic of comparison. The ICC values, ranging between 
.74 and 0.90 in patients with schizophrenia, and between 
.59 and 0.87 in patients with bipolar I disorder, as well as 
their comparison in both samples confirm the statistical 
similarity between the corresponding coefficients with the 
exception of VFT and VLT-D. 
Dimensional structure and relationship with other 
variables. The dimensional structures, both for the sample 
of patients with schizophrenia and those with bipolar I 
disorder, are defined by a single factor that explains 
approximately 50% of the observed variance (see Table 2). 
Table 1 Intraclass correlation coefficients of the SCIP in patients with schizophrenia and bipolar I disorder, and Feldt’s W.
 Schizophrenia Bipolar I Disorder  
Sub-test n ICC n ICC Feldt’s W
VLT-I 122 .76 74 .75 .960
WMT 122 .80 74 .77 .870
VFT 122 .81 74 .67 .576*
VLT-D 121 .74 74 .59 .634*
PST 122 .75 74 .82 1.389
Total SCIP 121 .90 74 .87 .769
Note. VLT-I = Verbal Learning Test-Immediate; WMT=Working Memory Test; VFT = Verbal Fluency Test; VLT-D= Verbal Learning Test-
Delayed; PST = Processing Speed Test; Total SCIP= SCIP total score.
* p < .05.
Table 2 Dimensional structure of the SCIP in patients with 
schizophrenia and bipolar I disorder, and Tucker’s C 
coefficient. 
Sub-tests  Schizophrenia Bipolar I Disorder 
VLT-I .78 .77
WMT .75 .71
VFT .70 .75
VLT-D .64 .80
PST .64 .53
Eigenvalue 2.49 2.61
% variance 49.79 52.21
Tucker’s C .99
C. of identity .99
Note. VLT-I = Verbal Learning Test-Immediate; WMT=Working 
Memory Test; VFT = Verbal Fluency Test; VLT-D= Verbal 
Learning Test-Delayed; PST = Processing Speed Test.
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Table 3 Correlations between the SCIP and the neuropsychological battery in patients with schizophrenia and bipolar I 
disorder, and Fisher’s Z 
 Schizophrenia Bipolar I Disorder  
Subtests  Neuropsychological battery test(s) n r n r Fisher’s Z
VLT-I WMS-III Wordlist I  123 .55* 76 .67* −1.296
WMT WAIS-III Arithmetic 123 .45* 76 .39* .491 
 WMS-III Digit Span 123 .40* 76 .39* .080 
 WAIS-III Letter Number – Sequencing 122 .38* 76 .32* .460
VFT Semantic fluency 123 .44* 76 .25* 1.461 
 Trail Making A (time) 123 −.38* 76 −.45* .570 
 WAIS-III Digit Symbol - Coding 123 .39* 76 .49* −.837 
 WAIS-III Symbol search 122 .47* 76 .52* −.446
VLT-D WMS-III Wordlist II 123 .48* 76 .52* −.359
PST WAIS-III Digit Symbol - Coding 122 .57* 76 .61* −.413 
 WAIS-III Symbol search 121 .60* 76 .58* .206
Note. VLT-I = Verbal Learning Test-Immediate; WMT = Working Memory Test; VFT = Verbal Fluency Test; VLT-D = Verbal Learning Test-
Delayed; PST=Processing Speed Test.
 * p < .05.
The saturations of the various subtests for this factor range 
between .64 and .78 in patients with schizophrenia and 
between .53 and .80 in patients with bipolar I disorder, so 
they are all highly significant.
Although it is accepted that two factor structures are 
equivalent if the index of congruence and identity values 
are close to 1, there is no test of statistical significance for 
these indexes; however, van de Vijver (2003) proposes an 
approach to interpretation, which postulates that values 
greater than .95 indicate factor similarity. Thus, this study 
confirms the equivalency of the dimensional structures in 
the sample of patients with schizophrenia versus patients 
with bipolar I disorder. 
As seen in Table 3, all correlations of each subtest of 
the SCIP with the corresponding tests of the 
neuropsychological battery were statistically significant 
and moderate to high in both schizophrenia and bipolar 
patient samples; Fisher’s Z, calculated to compare these 
coefficients of correlation between the two samples, was 
not statistically significant in any of the cases, which 
indicates similarity of the correlations obtained in the two 
patient samples. 
Comparison between samples
Table 4 shows the mean SCIP scores at the baseline visit for 
patients with schizophrenia and those with bipolar I 
disorder, and the control group. As can be seen, in the 
comparison between the two patient samples, those with 
schizophrenia obtained lower scores on all subtests than 
those diagnosed with bipolar disorder who also had lower 
mean scores than the control group.
The multivariate analyses showed a group membership 
effect (F(10,546) = 12,111, p < .05). Pairwise comparisons with 
respect to patient samples only reached statistical 
significance in the case of subtests VLT-I and VLT-D (both p 
values < .05), with small effect sizes (d = -0.23 and d = 
0.30, respectively). However, in the case of the control 
Table 4 SCIP mean scores in patients with schizophrenia and bipolar I disorder, and Cohen’s d.
 Schizophrenia Bipolar I Disorder  Control Cohen’s d 
Sub-test n Mean SD n Mean SD n Mean SD B vs S C vs B C vs S
VLT-I 124 18.46 3.81 76 19.39 4.36 83 21.87 3.45 0.23 0.63 0.93
WMT 124 17.04 4.33 76 17.29 3.88 83 19.59 3.20 0.06 0.65 0.65
VFT 124 14.34 5.40 76 14.42 5.32 83 19.48 5.59 0.01 0.93 0.94
VLT-D 124 4.56 2.25 76 5.26 2.42 83 6.59 1.89 0.30 0.62 0.96
PST 124 9.10 2.89 76 9.11 2.73 83 12.54 2.83 0.01 1.23 1.20
Total SCIP 124 63.51 13.45 76 65.47 13.65 83 80.07 10.58 0.14 1.20 1.41
Note. VLT-I = Verbal Learning Test-Immediate; WMT = Working Memory Test; VFT = Verbal Fluency Test; VLT-D = Verbal Learning Test-
Delayed; PST=Processing Speed Test; Total SCIP = SCIP total score; SD = Standard Deviation; S = Schizophrenia; B = Type I bipolar 
disorder; C=Control group.
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group, scores on all subtests were significantly higher than 
scores obtained from either patient sample (all p values 
< .05), with very similar effect sizes in both diagnostic 
groups ranging from 0.62 for VLT-D and 1.23 for PST in those 
with bipolar I disorder, and 0.65 WMT and 1.20 for PST in 
individuals with schizophrenia. 
As for the SCIP total score, type of sample showed a 
statistically significant effect (F(2,276) = 51,390, p < .05). 
Subsequent analyses showed that these differences came 
from the comparison of the control group with both the 
sample of patients with bipolar disorder (p < .05; d = 1.20) 
and those diagnosed with schizophrenia (p < .05; d = 1.41), 
while they disappeared when the two patients samples 
were compared (p = .09; d = 0.14). 
Regarding the neuropsychological battery, schizophrenia 
patients performed slightly worse than bipolar I patients in 
nine of the thirteen subtests, and both groups performed 
worse than controls on all subtests (Table 5). 
A significant difference was found in the multivariate 
analysis of variance comparing the subtest scores from the 
three samples (F(26,408) = 5.981, p < .05). The univariate 
comparisons between patient groups were not significant 
for any of the subtests (all p values > .05). However, when 
comparing each group of patients with the control group, 
these differences were statistically significant for all the 
subtests (all p values < .05) and their magnitudes were 
substantial, with Cohen’s d scores ranging from 0.74 (word 
list I and vocabulary) to 1.62 (digit symbol-coding) in 
schizophrenia patients and from 0.71 (arithmetic) to 1.55 
(TMT-A time to complete) in bipolar patients. In general, 
both patient groups showed a poorer performance than 
controls on measures of processing speed/attention (Digit 
symbol-coding, Symbol search and TMT-A), verbal learning, 
semantic fluency and executive functions (WCST, TMT-B), 
with large effect sizes. Similarly, both groups were 
cognitively more impaired than controls on working memory 
(medium-large ES) and on verbal memory subtests (medium 
ES).
Discussion
The purpose of this study was to compare cognitive 
impairment in one sample of patients with schizophrenia and 
another with bipolar I disorder using a screening test, the 
SCIP, which may be helpful in routine clinical practice 
because it can be easily administered and corrected by 
healthcare professionals. This study is original in its design, 
as there are few comparisons in the scientific literature of 
screening methods for detection of neurocognitive 
impairment in severe mental illnesses such as schizophrenia 
and bipolar disorder. In the scientific review performed on 
the psychometric properties of screening tools for cognitive 
impairment, we were able to find similar studies only in the 
area of cognitive disorders associated with dementia or 
stroke (Donald & Van Til, 2001; Pohjasvaara et al., 2001; 
Tuijl, Scholte, de Craen, & van der Mast, 2012), but not in 
patients with severe psychiatric disorders. The early 
detection of cognitive impairment in these disorders is 
important because cognitive skills are intimately linked with 
successful daily functioning, and the severity of the cognitive 
impairment in schizophrenia and bipolar disorders has been 
directly linked to greater functional disability (Bonnín et al., 
2012; Bowie et al., 2010; Martínez-Arán et al., 2007; Tabarés-
Seisdedos et al., 2008). Early detection of cognitive deficits 
using screening instruments such as the SCIP will contribute 
to the selection of optimal treatments in our clinical 
practices (Balanzá-Martínez et al., 2010), and may provide 
more objective criteria on which to weight the relative 
merits of seeking additional consultation from 
neuropsychology, neurology, and radiology.
The results reported here offer psychometric evidence to 
support the use of the SCIP for screening cognitive 
impairment in schizophrenia and bipolar I disorder. The 
characteristics of the SCIP were examined and compared in 
terms of internal consistency, temporal stability, 
dimensional structure and criterion validity in one sample 
of patients with schizophrenia and one with bipolar I 
Table 5 Subtest mean scores, standard deviations, and Cohen’s d in schizophrenia, bipolar I disorder and control group.
 Schizophrenia Bipolar I Control Cohen’s d
Subtest n Mean SD n Mean SD n Mean SD B vs S C vs B C vs S
Word list I 90 29.09 6.29 57 29.14 6.26 75 34.33 6.68 0.01 0.83 0.84
Word list II 90 5.73 2.82 57 5.65 3.00 75 7.80 2.75 −0.03 0.75 0.74
Digit symbol-coding 90 52.46 18.38 57 54.96 20.09 75 82.76 19.04 0.13 1.42 1.62
Symbol search 90 23.98 9.80 57 24.37 .26 75 37.08 8.89 0.04 1.40 1.39
Arithmetic 90 10.37 3.45 57 10.47 2.86 75 12.73 3.38 0.03 0.71 0.69
Digits 90 13.86 3.80 57 13.98 3.93 75 17.41 4.05 0.03 .86 0.91
Letters and numbers 90 8.01 2.56 57 8.25 3.01 75 11.21 2.46 0.08 1.10 1.27
TMT-Aa 90 49.88 20.79 55 47.22 13.85 75 28.13 11.06 0.14 1.55 1.27
TMT-B*b 90 123.52 59.83 55 126.98 51.44 75 68.28 24.84 −0.06 1.53 1.17
Semantic fluency 90 18.80 5.63 57 19.63 6.00 75 25.60 7.97 0.14 0.83 1.00
Vocabulary 90 39.32 11.49 57 39.14 12.20 75 46.53 7.24 −0.01 0.76 0.74
WCST-E 90 40.07 24.00 57 39.60 21.90 75 20.83 15.21 0.02 1.02 0.94
WCST-PE 90 25.49 19.70 57 27.53 22.31 75 11.20 8.75 −0.10 1.02 0.91
Note. WCST-E = Number of total errors; WCST-PE = Number of perseverative errors. 
 a Excluding patients with time to complete > 150 seconds.
 b Excluding participants with time to complete > 400 seconds.
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disorder. As for the reliability of the scale, acceptable 
values are obtained both with Cronbach’s alpha and ICCs, 
suggesting that, when applied to these samples of patients, 
the SCIP measures cognitive functions accurately and also 
has temporal stability in such measurements when 
administered on several occasions. In regard to the validity 
of the SCIP, the results suggest the existence of a single 
general cognitive factor that supports the concurrent 
validity of the test. Regarding the comparison of 
psychometric properties between the two patient samples, 
the results lead us to conclude that the SCIP has statistically 
similar psychometric properties in both samples. Therefore, 
it is an instrument that provides equally reliable and valid 
scores for assessing cognitive impairment in patients 
diagnosed with schizophrenia and those with bipolar I 
disorder (Guilera et al., 2009; Pino et al., 2008). The 
usefulness of these findings is that the SCIP user can be 
certain that the instrument is appropriately measuring the 
cognitive impairment of the patient diagnosed with either 
schizophrenia or bipolar I disorder. 
The comparison of cognitive impairment quantified by 
the SCIP total score in the patient groups suggests that both 
groups show significant impairment but show little 
difference from each other, with similar results apparent in 
the deficits observed on all tests from the more extended 
neuropsychological battery. The extended battery offered 
no compelling evidence of cognitive differences between 
the schizophrenia and bipolar disorder groups, aside from 
small effect sizes suggesting slightly more impairment in 
the schizophrenia group on the test of semantic fluency 
and one test of processing speed (Digit Symbol Coding). The 
SCIP also offered little compelling evidence of a difference 
between the schizophrenia group and the bipolar I disorder 
group aside from a small effect size difference for total 
score and a small to medium effect difference for 
immediate and delayed verbal recall, with all differences 
suggesting more impairment in the schizophrenia group. 
The learning and memory discrepancy was also suggested 
in the relatively greater impairment in the schizophrenia 
sample vs. controls, showing a large effect size, compared 
to the medium effect sizes in the bipolar disorder sample 
vs. controls. The profile was not observed in the verbal 
learning and memory measures from the extended 
neuropsychological battery (e.g., WMS-III Word List I and 
II), both of which showed similar impairment in both patient 
samples relative to the healthy control groups. Compared 
to the Verbal Learning Tests from the SCIP (e.g., 10 words 
tested 3 times immediate, and again after a 5 to 10 minute 
delay), the Word List Tests (12 words tested 4 times, and 
again after a 25 to 35 minute delay) would be expected to 
have a higher ceiling than the SCIP that might explain some 
of the apparent discrepancy if the bipolar patients were 
more likely to achieve the maximum score. Regardless, the 
results from both the SCIP and the extended battery are 
consistent with previous comparative studies that have 
demonstrated few qualitative differences with respect to 
the cognitive performance profile of patients with 
schizophrenia and patients with bipolar disorders, despite 
several suggestions of quantitative differences implicating 
less impairment in bipolar disorders (Balanzá-Martínez et 
al., 2005; Daban et al., 2006; Martínez-Arán et al., 2002; 
Tabarés-Seisdedos et al., 2008). More similarities between 
the two disorders with respect to neurocognitive 
performance were found in patients with greater chronicity 
or disease progression (Lewandowski, Cohen, & Ongur, 
2011). Neurocognitive assessment in the early stages of the 
disorder enables early detection of abnormalities and more 
effective intervention in these patients (Fuentes-Durá et 
al., 2012; Martínez-Arán et al., 2011; Vieta et al., 2012) as 
well as prevention of poorer illness course and greater 
disability (Guilera et al., 2012). 
In conclusion, the results observed in this study indicate 
that SCIP is a good screening tool for cognitive deficits in 
schizophrenia and bipolar disorder, providing a comparable 
assessment of cognitive function in these severe mental 
disorders. The brevity and ease of administration of the 
SCIP as a screening tool for detection of cognitive 
impairment are important advantages that would make this 
tool a cost-effective and addition of a variety of research 
applications, particularly in clinical trials for objective 
quantification of potential benefits or adverse effects of 
medications. With relatively minimal training, the SCIP can 
be administered and scored by a variety of healthcare 
professionals, rendering it suitable for a wide spectrum of 
clinical applications in schizophrenic and bipolar patients, 
but with particular value to the necessity of referring 
patients with significant impairments for more extensive 
neuropsychological examinations. It should be emphasized 
that the SCIP was not developed to supplant referral for 
evaluation and treatment recommendations from a 
neuropsychologist where such facilities exist (Rosa et al., 
2011; Vieta, 2011), but it was developed to assist early 
screening and to provide objective criteria on which to 
base treatment decisions in the many clinical settings that 
lack the time and resources for more thorough examinations, 
and to offer objective evidence to support referrals for 
additional consultation. 
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